<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580954</url>
  </required_header>
  <id_info>
    <org_study_id>17/247-E</org_study_id>
    <nct_id>NCT03580954</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation in Primary Progressive Aphasia</brief_title>
  <official_title>Transcranial Magnetic Stimulation in Primary Progressive Aphasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary progressive aphasia (PPA) is a clinical syndrome characterized by the
      neurodegeneration of language brain systems. Three main clinical variants are currently
      recorgnized (nonfluent, semantic, and logopenic PPA). Nowadays, there are no effective
      treatments for this disorder.

      Transcranial Magnetic Stimulation (TMS) is a technique based on the principle of
      electromagnetic induction of an electric field in the brain. It has been used as a
      non-invasive therapy in different disorders, such as depression, bipolar disorder,
      Parkinson's disease, and in the rehabilitation of post-stroke aphasia. Recent studies have
      shown how repetitive TMS improved language characteristics in Alzheimer's disease, and there
      are initial data in patients with PPA.

      This research project investigates the effect of repetitive TMS in patients with PPA.
      Investigators will perform a personalized TMS treatment for each patient (brain region, type
      of stimulation/inhibition, etc.), according to the specific characteristics of each patient
      and with the final aim to generate a computational model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in spontaneous speech (main primary endpoint)</measure>
    <time_frame>2 months (at baseline and at the end of the treatment)</time_frame>
    <description>Picture and story description task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in oral naming</measure>
    <time_frame>2 months</time_frame>
    <description>Object naming test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in reading</measure>
    <time_frame>2 months</time_frame>
    <description>Story and words reading test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in repetition</measure>
    <time_frame>2 months (at baseline and at the end of the treatment)</time_frame>
    <description>Non-words and sentence repetition task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in brain metabolism</measure>
    <time_frame>2 months (at baseline and at the end of the treatment)</time_frame>
    <description>Brain metabolism measured using 18F-FDG-PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical impression of change</measure>
    <time_frame>2 months (at baseline and at the end of the treatment)</time_frame>
    <description>Patient's clinical impression of change (from 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain cortical electrical activity</measure>
    <time_frame>2 months (at baseline and at the end of the treatment)</time_frame>
    <description>Changes in the brain cortical electrical activity measured using quantitative electroencephalography (EEG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in global cognition</measure>
    <time_frame>2 months (at baseline and at the end of the study)</time_frame>
    <description>Addenbrooke's Cognitive Examination III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical impression of change</measure>
    <time_frame>2 months</time_frame>
    <description>Caregiver's clinical impression of change (from 0 to 10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Primary Progressive Aphasia</condition>
  <arm_group>
    <arm_group_label>Repetitive TMS (estimulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Repetitive TMS (inhibition)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation</intervention_name>
    <description>Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.</description>
    <arm_group_label>Repetitive TMS (estimulation)</arm_group_label>
    <arm_group_label>Repetitive TMS (inhibition)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be clinically diagnosed of PPA according to current diagnostic criteria
             (Gorno-Tempini et al. 2011) with PET-FDG confirmation.

          -  Clinical Dementia Rating 0-1.

        Exclusion Criteria:

          -  Contraindications for TMS or MRI

          -  History of epilepsy

          -  Pregnancy

          -  Other language disorder previous to the diagnosis of PPA

          -  Neuroimaging not suggestive of PPA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Cl√≠nico San Carlos.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.madrid.org/cs/Satellite?c=Page&amp;cid=1142655223186&amp;pagename=HospitalClinicoSanCarlos%2FPage%2FHCLN_contenidoFinal</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Jordi A Matias-Guiu</investigator_full_name>
    <investigator_title>Principal Investigator. PhD MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

